Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Roche NSCLC drug receives positive CHMP opinion
Tarceva is a once-daily, oral, non-chemotherapy treatment for the treatment of advanced or metastatic NSCLC. The CHMP positive opinion is based on EURTAC study data that demonstrated Tarceva
Tarceva is a once-daily, oral, non-chemotherapy treatment for the treatment of advanced or metastatic NSCLC. The CHMP positive opinion is based on EURTAC study data that demonstrated Tarceva
As per the terms of the agreement, Bristol-Myers Squibb will take over all of Amira’s issued and outstanding shares of capital stock and stock equivalents. Bristol-Myers Squibb will
RG1068, a synthetic version of the hormone secretin, is known to both stimulate the secretion of pancreatic fluid into the pancreatic ducts and to increase blood flow to
The lawsuit covers Pronova BioPharma’s US patent no 7,732,488, US patent no. 7,678,930 and US patent no. 7,718,698. The patents entitled, ‘Pharmaceutical Composition Comprising Low Concentrations of Environmental
CHMP’s decision was backed by the positive results of a Phase III RADIANT-3 (RAD001 In Advanced Neuroendocrine Tumors) trial which demonstrated that the patients with advanced pancreatic NET
Sublinox, based on Orexo’s sublingual tablet technology is indicated as a short term treatment of insomnia. The tablet is a sublingual orally dissolving tablet that is placed under
A subsidiary of Glenmark Pharmaceuticals Limited India (GPL), GPSA’s GRC 15300 is an inhibitor of the TRPV3 and has demonstrated significant pharmacokinetic profile in the trial. The results
Dutasteride and tamsulosin hydrochloride capsules of Watson Pharma are the generic version of GSK‘s JALYN, which is used to treat symptomatic benign prostatic hyperplasia (BPH) in men suffering
The company plans to call for an end-of review meeting with the FDA to comprehend the details of the CRL and to discuss regarding further steps to be
The investment allows HBYS commercial team to also sell third party products in all provinces in China. HBYS will invest $3.2m for a 60% equity interest in NBHG